HC Wainwright Reiterates “Buy” Rating for Precigen (NASDAQ:PGEN)

HC Wainwright reissued their buy rating on shares of Precigen (NASDAQ:PGEN) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $6.00 target price on the biotechnology company’s stock, up from their prior target price of $4.00.

Separately, JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.00.

Precigen Trading Up 18.6 %

Shares of Precigen stock opened at $1.34 on Thursday. Precigen has a 1 year low of $0.65 and a 1 year high of $1.93. The firm’s 50-day moving average is $0.93 and its 200 day moving average is $1.06.

Institutional Trading of Precigen

A number of institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its position in Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 12,578 shares during the period. Exchange Traded Concepts LLC raised its stake in Precigen by 10.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 15,525 shares during the last quarter. Stifel Financial Corp lifted its holdings in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after buying an additional 16,486 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.